Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 688 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Influenza A Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT02532283
View directory record Official record
Conditions
Influenza A Virus
Interventions
JNJ-63623872, Placebo, Oseltamivir
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Fresno, California • Long Beach, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

NCT04074928
View directory record Official record
Conditions
Influenza, Human, Virus Diseases
Interventions
QIVc, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 47 Months
Enrollment
2,414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
47
States / cities
Mobile, Alabama • Anaheim, California • Downey, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

NCT01658800
View directory record Official record
Conditions
Influenza
Interventions
VAX161C vaccine
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
South Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 4 Interventional Results available

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

NCT02609399
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Peramivir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI

NCT06229444
View directory record Official record
Conditions
Influenza, Influenza A, Influenza B, COVID-19, Respiratory Syncytial Virus (RSV)
Interventions
ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content, No Intervention
Behavioral
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
17,043 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

NCT03058692
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Multimeric-001 Vaccine, Placebo, Quadrivalent Recombinant Seasonal Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

NCT01610245
View directory record Official record
Conditions
Influenza
Interventions
Nitazoxanide, Oseltamivir, Placebo Oral Tablet, Placebo Oral Capsule
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
13 Years to 65 Years
Enrollment
1,941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
136
States / cities
Birmingham, Alabama • Dothan, Alabama • Hoover, Alabama + 121 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Not applicable Interventional Results available

A Study of the GRIP Influenza and SARS-CoV-2 POC Assays

NCT05674370
View directory record Official record
Conditions
COVID-19, Influenza
Interventions
GRIP Electronic Diagnostic Chip, Laboratory-based nucleic acid amplification tests (NAATs)
Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

NCT02635724
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 25, 2026, 3:08 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

NCT01776541
View directory record Official record
Conditions
Pandemic H5N1 Influenza
Interventions
Adjuvanted H5N1 pandemic influenza vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 64 Years
Enrollment
979 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Miami, Florida • St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

NCT00943488
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 25, 2026, 3:08 PM EDT
Terminated Phase 3 Interventional Results available

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

NCT00610935
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
96
States / cities
Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695130
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

NCT07121192
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
22
States / cities
Anniston, Alabama • Fair Oaks, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 25, 2026, 3:08 PM EDT
Completed No phase listed Observational

BD Veritor™ At-Home and BD Veritor™ Professional

NCT05352581
View directory record Official record
Conditions
Upper Respiratory Infection
Interventions
BD Veritor At-Home, BD Veritor Professional
Diagnostic Test
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
2 Years and older
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
Coconut Creek, Florida • Palm Springs, Florida • Pembroke Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 25, 2026, 3:08 PM EDT
Not listed Phase 1 Interventional

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

NCT04629105
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Biological · Other
Lead sponsor
Longeveron Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 1 Interventional

VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old

NCT00973895
View directory record Official record
Conditions
Influenza A Virus, H1N1 Subtype, Novel Swine-Origin
Interventions
VRC-FLUDNA057-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

NCT01573312
View directory record Official record
Conditions
Influenza
Interventions
ASO3 Adjuvant, Influenza A/H5N1 Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 25, 2026, 3:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations

NCT00001681
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 3:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.

NCT05728970
View directory record Official record
Conditions
SARS-CoV-2, Influenza A, Influenza B, COVID-19
Interventions
LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
716 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Garden Grove, California • Lomita, California • DeLand, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

NCT02680002
View directory record Official record
Conditions
A/Vietnam/H5N1 Influenza Virus
Interventions
7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored in vials), MF59, MF59 (stored as monobulk)
Biological · Other
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Atlanta, Georgia • Council Bluffs, Iowa • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 25, 2026, 3:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

NCT00979602
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
4,048 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 25, 2026, 3:08 PM EDT